Cargando…

Advancing Risk Assessment of Intermediate Risk Prostate Cancer Patients

The individual risk to progression is unclear for intermediate risk prostate cancer patients. To assess their risk to progression, we examined the level of genomic instability in circulating tumor cells (CTCs) using quantitative three-dimensional (3D) telomere analysis. Data of CTCs from 65 treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drachenberg, Darrel, Awe, Julius A., Rangel Pozzo, Aline, Saranchuk, Jeff, Mai, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627662/ https://www.ncbi.nlm.nih.gov/pubmed/31226731 http://dx.doi.org/10.3390/cancers11060855

Ejemplares similares

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy
por: Wark, Landon, et al.
Publicado: (2019)

Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level
por: Rangel-Pozzo, Aline, et al.
Publicado: (2020)

The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
por: Kang, Ho Won, et al.
Publicado: (2017)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Environmental concentrations, characteristics and risk assessment of microplastics in water and sediment along the Western Cape coastline, South Africa
por: Julius, Danielle, et al.
Publicado: (2023)

Genomic Instability in Circulating Tumor Cells
por: Freitas, Monique Oliveira, et al.
Publicado: (2020)

MRI for managing intermediate & low risk prostate cancer
por: Padhani, Anwar R
Publicado: (2014)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Henk, G. van der Poel, et al.
Publicado: (2016)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Krishnananthan, Nishanth, et al.
Publicado: (2016)

Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients
por: Rangel-Pozzo, Aline, et al.
Publicado: (2022)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection
por: Roscigno, Marco, et al.
Publicado: (2018)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Thoracoabdominal Approach for Large Retroperitoneal Masses: Case Series and Review
por: Venkat, Siv, et al.
Publicado: (2019)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Active surveillance and focal therapy for low-intermediate risk prostate cancer
por: Klotz, Laurence
Publicado: (2015)

Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
por: Oh, Jong Jin, et al.
Publicado: (2021)

Urinary exosomal microRNA profiling in intermediate-risk prostate cancer
por: Kim, Mee Young, et al.
Publicado: (2021)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database
por: Agrawal, Rishabh, et al.
Publicado: (2022)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center
por: Ahmed, Shahida, et al.
Publicado: (2015)

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
por: Cyll, Karolina, et al.
Publicado: (2022)

Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
por: Ozyigit, Gokhan, et al.
Publicado: (2019)

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts
por: Merrick, Gregory S., et al.
Publicado: (2015)

Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2018)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
por: Harder, Nathalie, et al.
Publicado: (2018)

Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer
por: Alyamani, Najlaa, et al.
Publicado: (2021)

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates
por: Sorce, Gabriele, et al.
Publicado: (2022)

Pelvic leiomyoma associated with intermediate risk prostate cancer: A case report
por: Ben Hadj Alouane, Houssem, et al.
Publicado: (2023)

Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
por: Lodeta, Branimir, et al.
Publicado: (2023)

Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer
por: Belkacemi, Yazid, et al.
Publicado: (2023)

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
por: Gillessen, Silke, et al.
Publicado: (2023)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
por: Kang, Ho Won, et al.
Publicado: (2016)

Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy
por: Zhang, Hong, et al.
Publicado: (2021)

p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture
por: Rangel-Pozzo, Aline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pf0fbka1t14j74ek2p7n2aaip9